From: GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology
 | Agonist group | Antagonist group | P |
---|---|---|---|
Patients (n) | 32 | 32 | Â |
Age (years) | 33.2 ± 3.0 | 32.5 ± 3.0 | 0.39 |
BMI (kg/m2) | 23.5 ± 3.2 | 23.2 ± 3.0 | 0.48 |
Duration of infertility (years) | 4.4 ± 3.0 | 4.1 ± 3.0 | 0.33 |
Infertility | Â | Â | 0.11 |
Primary | 56.2% (18/32) | 78.1% (25/32) | Â |
Secondary | 43.8% (14/32) | 21.9% (7/32) | Â |
Tobacco use (%) | 3.1% (1/32) | 0 (0/32) | 0.31 |
Regular alcohol use | 12.5% (4/32) | 3.1% (1/32) | 0.35 |
Etiology | Â | Â | 0.59 |
Male factor | 50% (16/32) | 53.1% (17/32) | Â |
Idiopathic | 34.4% (11/32) | 21.9% (7/32) | Â |
Tubal factor | 9.3% (3/32) | 18.7% (6/32) | Â |
Male + Tuboperitoneal | 6.3% (2/32) | 6.3% (2/32) |  |
Total dose FSH (UI) | 2185.5 ± 617 | 1877.3 ± 817 | 0.09 |
Total dose LH (UI) | 1094.5 ± 258 | 1026.5 ± 385 | 0.87 |
Time of stimulation (days) | 11 ± 1.8 | 10.4 ± 3.2 | 0.82 |
Follicles (n) (hCG day) | Â | Â | Â |
Total (≥10 mm) ≥16 mm | 15.9 ± 8.3 6.9 ± 3.1 | 17.7 ± 9.2 7.5 ± 3.6 | 0.49 0.47 |
≥18 mm | 4.1 ± 2.1 | 4.1 ± 1.8 | 0.65 |
Retrieved oocytes: | Â | Â | Â |
Total | 12.5 ± 6.9 | 13.4 ± 7.0 | 0.57 |
Metaphase II stage | 9.3 ± 5.9 | 9.8 ± 6.0 | 0.77 |
Metaphase I stage | 1.3 ± 1.5 | 1.4 ± 1.4 | 0.22 |
Germinal vesicle stage | 1.3 ± 2.5 | 0.9 ± 1.4 | 0.88 |
Implantation rate | 29% (18/62) | 27.4% (17/62) | 1.00 |
Pregnancy rate | 40.6% (13/32) | 37.5% (12/32) | 0.79 |